Ultra-short-acting β1-blocker
Landiolol hydrochloride
Brand names: Rapibloc
Adult dose
Dose: IV: 10–40 micrograms/kg/min infusion; loading possible per BNF/SmPC
Route: IV
Frequency: infusion
Clinical pearls
- Rapid heart-rate control in supraventricular tachyarrhythmia/peri-operative
- Half-life ~4 min — easily titratable; cardioselective
Contraindications
- Severe bradycardia
- Sick sinus syndrome
- 2nd/3rd degree AV block
- Cardiogenic shock
- Severe hypotension
- Decompensated heart failure
- Pulmonary hypertension
Side effects
- Bradycardia
- Hypotension
- Bronchospasm
Interactions
- Calcium-channel blockers
- Digoxin
- Other negative inotropes
Monitoring
- ECG
- BP
- HR continuously
Reference: BNF; ESC; SmPC; https://bnf.nice.org.uk/drugs/landiolol-hydrochloride/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Cervical Cerclage Criteria (Short Cervix / Preterm Risk) · Preterm Labour
- Brief Pain Inventory — Short Form (BPI-SF) · Pain
- PHQ-2 Depression Screen · Diagnosis
- Montreal Cognitive — Short Screening for Substance Misuse · Substance Misuse Screening
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines